Jonathan Solomon

Jonathan Solomon Ph.D. is a director in the department of Chemical Genetics at Novartis Biomedical Research and has worked in early-stage drug discovery for over 20 years.  For the past ten years he’s focused on targeted protein degradation, particularly on molecular glue degraders. He has published work on the structure of the DCAF15-indisulam-RBM39 ternary complex, the discovery of CRBN glue degraders for the Helios and WIZ transcription factors and the identification of the first VHL glue degrader that targets CDO1.  Jonathan is interested in both developing molecular glue degraders into therapeutics and discovering the best ways to identify novel glue degrader starting points.